Revvity Beats Q2 Estimates, Guides Above Consensus, Divests China Unit
RVTY sits 43% above its 52-week low of $81.22.
Summary
Revvity delivered a strong Q2 with adjusted EPS of $1.41, well above the $1.18 a year ago, and revenue of $730M, beating expectations. The company also announced the divestiture of its China Immunodiagnostics business, which accounted for about 6% of 2025 revenue, expected to close by end of 2027. Pro forma results excluding that unit still showed solid growth, with adjusted EPS of $1.41 including a $0.11 tariff refund benefit. Full-year guidance was raised to $5.30-$5.40 in adjusted EPS on revenue of $2.83-$2.86B, both above consensus. Diagnostics segment drove the beat with 12% pro forma revenue growth and margin expansion to 30.4%. The stock is trading near its 52-week high, and this report reinforces the positive momentum.
Updates
· SEC 8-K — The definitive agreement for the China IDX sale was signed July 31, 2026, for up to $200 million, subject to adjustments and conditions.
At the time of this announcement, RVTY was trading at $116.28 on NYSE in the Life Sciences sector, with a market capitalization of approximately $12.9B. The 52-week trading range was $81.22 to $118.30. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.